Age is a prognostic factor for the overall survival of multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.
In this retrospective analysis, we evaluated the impact of age on the outcome of multiple myeloma (MM) patients who received an autologous hematopoietic stem cell transplantation (auto-HCT) at our institution. A total of 1128 patients were divided into the older (> 70 years; 182/16%) and the younger (≤ 70 years; 946/84%) groups. Compared to the younger cohort, older patients had a higher ISS stage (ISS-II 57: 31% vs 215: 23%, ISS-III 52: 28% vs 211: 22%, P = 0.01), higher use of reduced-dose melphalan as conditioning regimen (140 mg/m² 59: 32% vs 29: 3% P = < 0.001) and a higher comorbidity index (HCT-CI median 3 vs 2, P = 0.01). Non-relapse mortality at 1-year post auto-HCT was significantly higher in older patients (7: 4% vs 9: 1%, HR 4.1, P = 0.005). Complete remission rates after auto-HCT for the older and the younger groups were 41% and 46%, respectively. With a median follow-up of 52 months, the 5-year PFS were 24% (95% CI 17-32%) and 37% (95% CI 33-40%) in the older and the younger group, respectively (HR 1.3, P = 0.02). 5-year OS for the older and the younger group were 56% (95% CI 47-64%) and 73% (95% CI 70-76%; P = < 0.001), respectively. Older age emerged as one of the predictors of shorter OS, but not PFS, in the multivariate classification and regression tree (CART) analysis. In conclusion, age ≥ 70 was associated with shorter PFS and OS in multiple myeloma patients who underwent an auto-HCT.